Tesofensine is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014

Clinical Data:

• Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
• Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons
• Anti-obesity Drugs: From Animal Models to Clinical Efficacy

Storage and Handling:
To preserve the stability and integrity of this product, store it in a cool, dry place, protected from direct sunlight. Handle Tesofensine with care and follow standard laboratory practices to ensure precise and reliable results.

Disclaimer:
This product is not intended for human or animal consumption. It is exclusively designed for research by qualified professionals. Any potential therapeutic applications should undergo rigorous exploration, validation, and further research, including clinical trials.